

Syncona Limited

Issue of shares pursuant to incentive scheme

17 November 2025

Syncona Ltd (the "Company"), a leading life science investor, today announces that a total of 334,788 new ordinary shares (representing approximately 0.055% of the Company's existing issued ordinary shares, excluding shares held in treasury) will be issued in satisfaction of realisations under the Company's long term incentive scheme. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the incentive scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 13 November 2025, £0.996 per ordinary share in the Company.

In accordance with the rules of the incentive scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading. It is expected that dealings will commence in the new ordinary shares on 20 November 2025.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clark
Tel: +44 (0) 20 3981 7940

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ALSEAKFLFLPSFFA